Deka Biosciences, based in Germantown, MD and led by CEO Dr. John Mumm, develops disease-specific Diakines designed to target the accumulation of dual and complementary cytokines into affected tissues to improve pharmacokinetics and pharmacodynamics. The company recently received an FDA notice to proceed for its IND to evaluate DK210 (EGFR) and is continuing clinical trials. It closed a $20M Series B2 financing to support advancement of its pipeline and drug product manufacturing. Management says the funds will be used to advance clinical programs and scale drug product manufacturing. Detlev Biniszkiewicz, Ph.D. of MPM BioImpact will join Deka’s board as part of the raise. Deka Biosciences is an early-stage biotech developing novel cytokine therapies (Diakines™) to treat cancer and inflammatory diseases such as Crohn’s, psoriasis, rheumatoid arthritis and sepsis. Its Diakines™ are disease-specific therapeutic proteins designed to maximize patient benefit through improved pharmacokinetics/pharmacodynamics via targeted delivery of dual and complementary cytokines to affected tissues or cells. The company applies precision medicine to ensure treatment of patients most likely to benefit from and respond to cytokine therapies. Deka intends to use the newly raised funds to advance research, expand talent acquisition, and further develop its platform. Specifically, the company plans to file an Investigational New Drug (IND) application for its lead oncology program and advance the lead compound into Phase I clinical trials. Deka raised $20M in a Series A from strategic and venture investors to support these initiatives.

Total raised

$40M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2023